Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.

Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.

<h4>Aim</h4>Long acting injectable (LAI) antipsychotics are an alternative to oral antipsychotic (OAP) treatment and may be beneficial for patients in the early stages of schizophrenia. This study aims to provide a comprehensive review on the efficacy of first-generation and second-gener...

Full description

Bibliographic Details
Main Authors:	Lulu Lian, David D Kim, Ric M Procyshyn, Diana Cázares, William G Honer, Alasdair M Barr
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0267808

Similar Items

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
by: David D. Kim, et al.
Published: (2021-07-01)

Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis.
by: Lik Hang N Lee, et al.
Published: (2018-01-01)

Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance
by: Heidi N. Boyda, et al.
Published: (2022-02-01)

Developing prediction models for symptom severity around the time of discharge from a tertiary-care program for treatment-resistant psychosis
by: Lik Hang N. Lee, et al.
Published: (2023-06-01)

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models.
by: Heidi N Boyda, et al.
Published: (2021-01-01)

Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines
by: Heidi N. Boyda, et al.
Published: (2020-12-01)

Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.
by: Heidi N Boyda, et al.
Published: (2013-01-01)

Prescribing practice of long-acting injectable antipsychotics
by: Jisha M Lucca, et al.
Published: (2020-01-01)

An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine.
by: Claire Wu, et al.
Published: (2014-01-01)

Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis
by: David D. Kim, et al.
Published: (2021-05-01)

Long acting injectable antipsychotics – Where are we?
by: Phani Prasant Mulakaluri
Published: (2015-01-01)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
by: John M. Kane, et al.
Published: (2023-03-01)

Long-acting injectable antipsychotics during pregnancy: An update
by: A. Paraschakis, et al.
Published: (2021-04-01)

Attitude and preferences towards oral and long-acting injectable antipsychotics in patients with psychosis in KwaZulu-Natal, South Africa
by: Krishanand R. Roopun, et al.
Published: (2020-07-01)

The Use of Long-Acting Injectable Antipsychotic Therapy for Schizophrenia
by: Jason Jiang, et al.
Published: (2018-09-01)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
by: JP Lindenmayer
Published: (2010-05-01)

Effect of long-acting antipsychotic treatment on psychiatric hospitalization rate in early psychosis patients: a naturalistic study
by: Raúl Sancho-Echeverria, et al.
Published: (2024-04-01)

The use of long-acting injectable antipsychotics in an acute psychiatric unit
by: G. Ortega-Hernández, et al.
Published: (2023-03-01)

Knowledge about antipsychotic long-acting injections: bridging that gap
by: Burns, T
Published: (2009)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
by: Francisco José Toja-Camba, et al.
Published: (2021-06-01)

The evolution of antipsychotic medication: a long-acting injectable formulation of a second-generation antipsychotic
by: Piet Oosthuizen
Published: (2006-06-01)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
by: Shubhra Mace, et al.
Published: (2019-07-01)

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
by: Kunal Maini, et al.
Published: (2021-07-01)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
by: Heidi J. Wehring, et al.
Published: (2011-06-01)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
by: Heidi J. Wehring, et al.
Published: (2011-01-01)

A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents
by: Thomas Dodsworth, et al.
Published: (2018-07-01)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
by: M.F. Tascón Guerra, et al.
Published: (2022-06-01)

Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension
by: Ric M Procyshyn, et al.
Published: (2020-01-01)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
by: Suda A, et al.
Published: (2018-09-01)

Expert Consensus on Long-acting Injectable Antipsychotic in the Treatment of Schizophrenia in Community
by: Chinese Schizophrenia Coordination Group, Chinese Society of Psychiatry, Chinese Society of General Practice
Published: (2022-10-01)

Long-Acting Injectable Antipsychotics—A Review on Formulation and In Vitro Dissolution
by: Magdalena Markowicz-Piasecka, et al.
Published: (2023-12-01)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
by: O. Vasiliu
Published: (2022-06-01)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
by: Riboldi I, et al.
Published: (2022-12-01)

Attitudes of European physicians towards the use of long-acting injectable antipsychotics
by: Maxine X. Patel, et al.
Published: (2020-03-01)

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
by: Petru Ifteni, et al.
Published: (2021-12-01)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
by: Leslie Citrome
Published: (2009-11-01)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
by: Pietrini F, et al.
Published: (2019-04-01)

Treatment effectiveness of shifting from risperidone long-acting injectable to first-generation long-acting injectable antipsychotics in patients with schizophrenia
by: Ching- Yin Chang, et al.
Published: (2019-01-01)

Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
by: Patel, R, et al.
Published: (2017)

Assessment of oral overlap with antipsychotic long-acting injectables initiated in an inpatient setting
by: Tran Jennifer T. PharmD, et al.
Published: (2023-06-01)